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ABSTRACT
This study examines whether the general level and rate of
change of fatigue over time is different for those rheumatoid arthritis (RA) patients with and those without a history of affective
disorder (AD). Four hundred fifteen RA patients from a national
panel had yearly telephone interviews to obtain fatigue and distress reports, and a one-time semistructured assessment of the
history of depression and generalized anxiety disorder.
Growth-curve analysis was used to capture variations in initial
fatigue levels and changes in fatigue over 7 years for those with
and without a history. RA patients with a history of major AD reported levels of fatigue that were 10% higher than those without
a history in the 1st year of the study. Their fatigue reports remained elevated over 7 years. Further analysis showed that the
effects of a history of AD on fatigue are fully mediated through
current distress, although those with a history had a significantly smaller distress–fatigue slope. Thus, a history of AD
leaves RA patients at risk for a 7-year trajectory of fatigue that
is consistently higher than that of patients without a history. The
elevation in fatigue reports is, at least in part, a function of enduring levels of distress.

(3–8). To date, this area of research has been limited to
predictors measured either concurrently or in close temporal
proximity with the fatigue report.
Although concurrent predictors are essential, a growing
body of research suggests that an important, but rarely examined, predictor of physiological symptoms such as fatigue is
the individual’s history of affective disorder (AD) (9–14). The
pathway from AD to physiological outcome is not known (15).
It has been suggested that the experience of AD, such as major
depression (MD), is associated with alterations at the cellular
level that remain abnormal even in remission, thus creating a
long-term risk for worse outcomes long after the episode
(16,17). For instance, altered biochemical processes following
MD may explain sustained sleep deprivation and thus higher
levels of fatigue in some patients (18). Alternatively, a link between past AD and symptom reports may be through an enduring personality characteristic such as neuroticism (N). N,
which is common among individuals with a history of AD
(19), is also associated with elevated symptom reporting (20)
and a vulnerability to negative emotion. Thus, the focus in this
literature is on factors associated with AD that create
long-term consequences for patients.
Our previous work examining the association between a
history of AD (11) and the future experience of symptoms of RA
was cross-sectional. To fully evaluate the sustained effect on fatigue, we asked whether those with such a history experience a
different course or trajectory of fatigue over time. The intent of
this analysis is to begin to explore whether the general level and
rate of change of fatigue over time (the fatigue trajectory) is different for those with and those without a history of AD.

(Ann Behav Med 2001, 23(1):34–41)
INTRODUCTION
Fatigue is a common and frequently debilitating problem
for people with rheumatoid arthritis (RA). Studies of fatigue
have focused on the underlying inflammatory process (1) and
fatigue’s association with increased disease activity (2), sleep
disturbance, pain, length of time with the diagnosis of RA, depressive symptoms, daily stressors, and functional disability

METHOD
The work was supported by a Clinical Science Grant from the National
Arthritis Foundation. This article was presented at the XIV World Congress of Sociology, Montreal, July 26 through August 1, 1998.

Participants
The National Rheumatoid Arthritis Study is a prospective
panel study that completed its 10th and final year in 1997
through 1998. The panel of 988 patients with classical or definite
RA (21) was recruited from a national, random sample of
board-certified rheumatologists (details of the recruitment are
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published elsewhere) (11). At the close of their 8th-year interview, the 508 patients remaining in the panel were asked if they
would be interested in participating in an additional interview
about their emotional and physical well-being. A total of 462
(91%) agreed to the follow-up interview, and 415 (90%) completed it. They were largely upper middle age (M = 58, SD =
9.7), married (68%), out of the labor force (65%), women (83%),
which is consistent with the 3:1 prevalence of RA among middle-age women compared to men and the relatively low employment rate found in similar samples of RA patients (22).
Procedures
The telephone interview lasted approximately 30 min. Current and lifetime Diagnostic and Statistical Manual of Mental
Disorders (4th ed. [DSM–IV]) (31) psychiatric diagnoses of MD
and generalized anxiety disorder (GAD) were obtained using
the Semi-Structured Assessment for the Genetics of Alcoholism
(SSAGA) (23). The SSAGA, based on the Diagnostic Interview
Survey (DIS) (24), is suitable for either telephone or
face-to-face administration by lay interviewers (25). Although it
offers the same reliability and validity as the DIS (26), the
SSAGA offers certain options that make it attractive for use in
the arthritis population, including the ability to link episodes of
MD or GAD to comorbidities and flares, as well as drug use, alcohol use, or both.
Interviewers completed approximately 20 hr of SSAGA
training. They were supervised by a clinical psychologist, and
every interview was edited for accuracy by a research staff
member with a master’s degree in psychology and several years
of experience with the development of the interview.
Measures
Demographic characteristics. Demographic variables include age, sex, education, family income, marital status, and
working status.
Fatigue associated with RA. Fatigue associated with RA
was measured by asking patients, “On a scale of 0 to 100, with 0
being no fatigue at all and 100 being the most fatigue possible,
how much arthritis fatigue did you feel in the past week?” Comparable scales have been employed successfully in other studies
of RA (27). This indicator of fatigue was used at each yearly interview from Years 2 through 8. Thus, we were able to trace fatigue reports over 7 years.
Distress. Distress was measured with the Center for Epidemiological Studies Depression Scale (CES–D) (28). Although
the CES–D scale was originally developed to measure depressive symptoms in community populations, recent concerns
about its discriminant validity suggest that researchers should
interpret scores more broadly as indicators of distress (29,30).
The CES–D is a 20-item questionnaire that reflects various
aspects of depression, including depressed mood, feelings of
guilt and worthlessness, loss of appetite, and sleep disturbance.
It yields a single summary score that ranges from 0 to 60. Good
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reliability and validity have been reported (28). The alpha reliability coefficient of the scale in this sample was .75.
Diagnosis of AD. DSM–IV (31) criteria to qualify for a diagnosis of MD include (a) depressed mood or loss of interest
and pleasure in things that the individual usually cared about or
enjoyed every day or nearly every day for 2 weeks or more at
some time in the past while experiencing impaired role functioning, and (b) four of eight symptoms: problems with appetite,
sleep, fatigue, energy, interest, self-worth, cognition, or suicidal
ideas. The episode could not be due to injury, illness, medication
or alcohol, childbirth, or the loss of a loved one within certain
time parameters. A diagnosis of current MD required that symptoms occurred within 3 weeks of the interview, whereas a diagnosis of lifetime MD required that the symptoms occurred anytime in the past but not the past 3 weeks.
DSM–IV criteria for a GAD include (a) excessive anxiety
and worry for 6 months; (b) difficulty controlling worry; and (c)
at least three of the following six symptoms experienced nearly
every day during the episode: restlessness, being easily fatigued,
difficulty concentrating or mind going blank, irritability, muscle
tension, sleep disturbance. Symptoms cannot be due to the direct effects of a substance or medical condition, they must manifest themselves in role impairment, and they cannot be exclusively coincident with mood disorder. Current GAD required all
of these criteria within the 6 months preceding the interview,
whereas lifetime GAD required the same criteria for 6 months in
the past prior to that time.
DSM–IV does not include criteria for a comorbid condition.
The scoring of both MD and GAD requires assigning a case that
meets criteria for both conditions to the MD diagnosis. However, because the emotional and physical outcomes of individuals with both MD and GAD are less positive (32), we classified
people who met full criteria for both MD and GAD as comorbid.
When the comorbid category is considered in the following
analyses, the number of “pure MD” and “pure GAD” is adjusted
to reflect those who belong in the comorbid category.
Statistical Analysis: Growth-Curve Models
Growth-curve analysis (33–40) was used to capture variations in initial fatigue levels and changes in fatigue over time
and to determine if a history of AD influences fatigue’s level and
temporal trajectory. We chose Hierarchical Linear Models
(HLM) for the analysis because of the hierarchical nature of the
data, with fatigue reports nested within years (33). HLM models
individual growth using Ordinary Least Squares (OLS) regression estimates and variations between individuals using maximum likelihood estimates. HLM is designed to estimate parameters despite the potentially biasing effects of individuals
contributing multiple observations (33,34,38,40).
Changes in fatigue over time are modeled at two levels. At
Level 1 (within individuals), the unit of analysis is the year. This
level consists of repeated observations of individuals over time
(years). The following equation is adapted from Bryk and
Raudenbush (32) to describe the linear growth curve for this
analysis:

36

Fifield et al.

Annals of Behavioral Medicine

Y ti = π 0i + π li a ti + e ti

for i = 1 … N individuals and Yti = fatigue score for
person i at time t
π0i = the intercept parameter indicates the estimated
fatigue level for each person in the 1st year of
this study, and π1i = the linear slope parameter
indicates the growth rate for each individual for
each year
ati = the measure of time (in this study, the year of the
interview for individual i)
eti = the error, usually assumed to be independently
and normally distributed with a mean of 0 and a
constant variance σ2
At Level 2 (between individuals), the unit of analysis is the
individual. The second level coefficients describe how variations in unchanging characteristics of the individual, such as
having a history of AD, can explain differences in intercepts
(initial fatigue level) and slopes (fatigue trajectory coefficients)
between individuals. We used the HLM4 (Version 4) program to
generate estimates of the variance and covariance components
of the growth-curve model and the estimates of the β0q coefficients (41).
The following equations describe the Level 2 relations (32):
Q0

π 0i = β00 + ∑ β0 qX0 qi + roi
q =1

Q1

π1i = β10 + ∑ β1qX1qi + r1i
Q =1

Xqi = measures of characteristics at the person level
for each individual i
β0q = the effects of the characteristics on the slope
and intercept parameters
roi and r1i = error terms that are assumed to be
uncorrelated with the characteristics and are
multivariate normally distributed with means of
0. The error terms represent unmeasured characteristics of individual i that do not change over
time.
Steps in the Analysis
We begin with a series of descriptive analyses to determine the prevalence of past and current AD, as well as the
general pattern of change in fatigue among the study participants. This step is essential because few theories exist regarding the likely shape of the fatigue trajectory (42). In the next
step, we estimate a baseline growth-curve model with time
(mean growth rate) as the only independent variable. This
model estimates individual OLS regression equations for all
415 participants. The baseline growth model also provides an
estimate of the average fatigue level in the 1st year of the
study and the average rate of change in fatigue from year to
year, across all individuals. The 415 intercepts and slopes from

this baseline growth model become the primary outcomes of
interest to explain in the remaining models.1
Because the shape of the fatigue trajectory is unknown, we
tested the possibility that a nonlinear model of change more adequately fits the data than do linear models. We tested a nonlinear
growth model by including time squared in this baseline model
(34,36,38,40,43) that tests for a curvilinear pattern in which fatigue increases quickly at first and then more slowly in later
years. The inclusion of this variable did not improve the fit of the
model; therefore, we maintain the more parsimonious linear
model throughout the analyses.
We next tested the importance of having had an AD on the fatigue trajectory coefficients. In the specific AD model, dummy
variables indicating whether an individual had a history of a specific disorder (MD, GAD, or both [comorbidity]) were used to explain differences in initial fatigue status and the fatigue growth
rate between individuals. In the combined AD model, a single
dummy variable indicating whether an individual had a history of
any disorder was used to explain differences in initial fatigue status and the fatigue growth rate between individuals.
Two rival explanations for the expected differences in fatigue were tested next. The first is that the duration of time with
RA explains differences in the fatigue trajectory (4). Therefore,
we included in the model years since diagnosis of RA at the start
of the study. The second explanation is that a history of AD may
be a risk factor for higher current fatigue only when current distress levels are elevated (3,6,44). To test the relation between
current distress and fatigue, distress was measured in two ways
in the same model (39,45,46). At the within-individual level,
current distress was measured as deviations from each individual’s own mean CES–D score across the 7 years. At the between-individual level, current distress was measured as average CES–D scores aggregated across the 7 years of the study.
Thus, we asked how much of the variation in fatigue was due to
changes in distress within individuals year to year and how
much was due to differences between individuals in aggregate
mean distress.2
RESULTS
Table 1 shows the distribution of lifetime and current diagnoses across study participants. Those meeting full criteria for
both MD and GAD are not combined in a separate comorbid cat1Because the time period for the study is arbitrary (1989–1995),
the 1st year of the study has no special meaning. Therefore, the choice
of the 1st year of the study as an “index year” in models presented in Table 2 is arbitrary (the intercept indicates fatigue in the 1st year of the
study because the year variable is coded as zero for the 1st year). We,
therefore, tested models with both the 4th year (middle) and the last
year (separately) coded as zero to see if the particular year chosen as the
index influences the results. The coefficients change very little, with no
substantive or statistical consequences for the conclusions of the analysis. We, therefore, proceed to the second level of analysis using the coefficients estimated by the linear growth-curve model (Table 2).
2In the final full model, the intercept, β , indicates fatigue scores
00
in the 1st year of the study for newly diagnosed people without a history
of AD and with average (across people) distress scores.
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egory in this table, and current diagnoses are not included in the
count of lifetime diagnoses. Six percent of the sample met criteria for current MD, whereas 15% met criteria for lifetime depression. Five percent met criteria for current GAD, and 4% met
lifetime criteria. Nearly 20 years had elapsed since the first AD
episode for those with a history of GAD, whereas only 7 years
had elapsed for those with MD. For most participants, affective
events occurred years prior to the diagnostic interview, and for
37%, the first episode occurred prior to the onset of RA.
The baseline fatigue growth-curve model in Table 2 reveals
that on average, patients reported initial fatigue scores in the
middle range of the scale (β00 = mean initial fatigue = 49.68,
95% confidence interval = 47.11–52.25), with scores increasing
by .5% per year (β01 = mean growth rate = 0.51, p = .026). The
significant coefficient for mean growth rate indicates that on average, fatigue increases over time. The chi-square value for the
TABLE 1
The Distribution of Lifetime and Current Diagnoses Across
Study Participants
Affective Diagnosis
Current major depression
Lifetime major depression
Current Generalized Anxiety Disorder
Lifetime Generalized Anxiety Disorder

%

n

6
15
5
4

26
61
21
17
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variance component is significant for both mean initial fatigue
(χ2 = 1,563.9, p = .0001) and mean growth rate (χ2 = 631.33, p =
.001). Therefore, we can infer that differences exist among the
415 people in their initial fatigue levels and in the rate of change
in fatigue over time. When the total variance was partitioned
into components, a little over one half was due to differences between individuals (523.26, or 56% of the variance), with the remainder due to within-individual variance in fatigue over time.
Including dummy variables indicating a history of a specific AD (MD, GAD, or comorbidity) reduced the variance by
3% (see Table 2, Specific AD model). In other words, 3% of the
true between-person variance (which itself was 56% of the total
variance) in initial fatigue is accounted for by history of AD status. Comorbidity was not associated with higher fatigue scores
(β03 = 8.19, p = .226). Although individuals with a history of
GAD reported average levels of initial fatigue that were comparable to those of individuals with a history of MD (GAD: β02 =
10.98, p = .094; MD: β01 = 10.92, p = .004), the coefficient was
significantly different only for those in the latter group.
When patients with a history of AD were combined into
one group, the results changed little (Table 2, Combined AD
model). Although initial fatigue was higher for those in the affective history group (47.31 + 10.46 = 57.77), there were no differences in the slopes or rate of change in fatigue between the
two groups (β11 = –.29, p = .605). On average, changes in fatigue
tended to be smaller year to year for the affective history group
compared to the no-history group.

TABLE 2
Coefficients of the Hierarchical Linear Models of Fatigue Trajectories, Baseline and Affective Disorder Models,
for Rheumatoid Arthritis (1989–1995)
Fixed Effects
Baseline fatigue growth-curve model
Mean initial fatigue (β00)
Mean growth rate (β01)
Specific AD model
Model to explain variance in initial fatigue level estimated
within individuals (intercepts, π0i)
No history (β00)
MD (β01)
GAD (β02)
Comorbid (combined MD+GAD) β03
Model to explain variance in growth rate estimated within
individuals (years, π1i)
No history (β10)
MD (β11)
GAD (β12)
Comorbid (combined MD+GAD) β13
Combined AD model
Model to explain variance in initial fatigue level estimated
within individuals (intercepts, π0i)
No history (β00)
History of AD (β01)
Model to explain variance in growth rate estimated within
individuals (years, π2I)
No history (β10)
History of AD (β11)

Coefficient

SE

t Ratio

p

49.68
0.51

1.31
0.23

37.94
2.23

.0001
.0260

47.31
10.92
10.98
8.19

1.47
3.69
6.57
6.76

32.10
2.96
1.67
1.21

.0001
.0040
.0940
.2260

0.58
–0.57
1.33
–0.91

0.26
0.66
1.17
1.20

2.21
–0.87
1.14
–0.76

.0270
.3850
.2560
.4480

47.31
10.46

1.47
3.09

32.17
3.39

.0001
.0010

0.58
–0.29

0.26
0.55

2.21
–0.52

.0270
.6050

Note. AD = affective disorder; MD = major depression; GAD = Generalized Anxiety Disorder.
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We next tested the possibility that some of the variance in
intercepts and slopes might be due to length of time living with
RA up to the start of the study. There was no support for the
“time with RA” explanation for the variations in fatigue; neither
the intercepts (β02 = 0.03, p = .83) nor the slopes (β12 = –0.00, p
= .68) were associated with differences in length of time with
RA (Table 3, Full model).
In addition, we tested whether changes in current distress,
or average aggregate distress, mediated the relation between a
history of AD and the fatigue trajectory. We included two variables in the analysis. The first variable tested the relation between changes in current distress and fatigue within individuals
(see Table 3, Model for distress to fatigue slope …). The second
variable tested the relation between average aggregate distress
(see Table 3, Mean aggregate distress score) and fatigue between individuals. Within individuals, the average coefficient
for the distress–fatigue slope was positive (Table 3, Full Model:
β10 = 1.02, p = .001), indicating that on average, increases in distress were associated with increases in fatigue among the study
participants. For a unit change in distress, fatigue increased by
1%. The variance around the average slope (1.02) is 0.46 (SD =
0.69). Therefore, for an individual whose slope is 1 SD above
this mean, the slope is 1.71, or more than one half an additional
percentage increase in fatigue. CES–D scores explained 11% of
the within-individual variance in fatigue compared to the baseline model. Examining the data between individuals, we found
that higher mean aggregate distress scores were associated with
higher initial fatigue levels (β03 = 1.79, p = .001), but a smaller
distress–fatigue slope (β13 = –0.03, p = .001). Thus, whereas the
average initial fatigue score for those with no history and average distress was 48.70, a person with distress just 4 points higher

than the average on the CES–D scale would have an average fatigue of 55.94 ((4X1.79) + 48.70 = 55.94). Mean aggregate
distress scores were not associated with a different rate of
change (growth) in fatigue over time (β23 = –0.02, p = .44).
Mean aggregate distress scores reduced the variance between
individuals (56% of the total variance) by 40%.
Because the coefficient for history of AD was no longer significant in the final model that included distress, we tested a
model in which mean aggregate distress mediates the association between a history of AD and current fatigue. To qualify as a
mediating variable, the relations among mean aggregate distress, history of AD, and fatigue must meet three conditions
(47). First, having a history of AD must be associated with
higher mean aggregate distress. We used a simple analysis of
variance model to test this association. Mean aggregate distress
scores were between 4 and 12 units higher for those with an affective history (F = 21.26, p = .0001, df = 3). Scheffé’s tests revealed that distress scores for patients with each disorder were
higher than those with no disorder. Second, an AD history must
be associated with fatigue. The initial significant association between a history and fatigue in the combined AD model (Table 3;
β01 = 10.46, p = .001) meets this condition. Third, mean aggregated distress must be associated with fatigue and should reduce
the initial association between a history and fatigue. In the full
model (Table 3), mean aggregated distress is associated with fatigue (β03 =1.79, p = .0001), and when this variable is included
in the analysis, the association between a history of AD and fatigue is substantially reduced and is no longer statistically significant (β01 = –.69, p = .80). This pattern of findings indicates
that a history of AD is associated with higher levels of distress
aggregated over a full 7 years, and higher levels of aggregate

TABLE 3
Coefficients of the Hierarchical Linear Models of Fatigue Trajectories, Baseline and Affective Disorder Models,
for Rheumatoid Arthritis Patients
Fixed Effects
Full model
Model to explain variance in initial fatigue level
estimated within individuals (intercepts, π0i)
No history, new RA Dx, average distress (β00)
History of affective disorder (β01)
Years with RA diagnosis at study start (β02)
Mean aggregate distress score (β03)
Model for distress to fatigue slope estimated within
individuals (β1i)
No history, new RA Dx, average distress (β10)
History of affective disorder (β11)
Years with RA diagnosis at study start (β12)
Mean aggregate distress score (β13)
Model to explain variance in growth rate estimated
within individuals (years, β2I)
No history, new RA Dx, average distress (β20)
Has an affective disorder Hx (β21)
Years with RA diagnosis at study start (β22)
Mean aggregate distress score (β23)

Coefficient

SE

t Ratio

p

48.70
–.69
0.03
1.79

1.79
2.75
0.12
0.14

27.21
–0.25
0.22
12.64

.0001
.8030
.8270
.0001

1.02
0.15
–0.00
–0.03

0.13
0.17
0.01
0.01

7.87
0.86
–0.41
–3.38

.0001
.3920
.6780
.0010

0.36
–0.18
–0.01
–0.02

0.36
0.56
0.02
0.03

2.44
–0.32
–0.18
–0.77

.0150
.7490
.8570
.4400

Note. Within individual: Time and distress. Between individual: Affective disorder status, Mean distress score across the study, and length time with an
RA diagnosis (in years) at the start of the study period. RA = rheumatoid arthritis; Dx = diagnosis; Hx = history.
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distress are associated with higher levels of fatigue but a smaller
distress–fatigue slope.
DISCUSSION
Our study shows the importance of examining both the history of AD and the current level of distress when explaining the
experience of fatigue over time among patients with RA. We
found that individuals meeting DSM–IV criteria for a history reported levels of fatigue in the 1st year of the study that were higher
and that remained higher over the entire study period compared to
those without a history of AD. This finding emerged despite the
fact that, in most cases, the episode predated the 1st year of the
study, and in many cases occurred as much as 30 years before the
diagnostic interview. We also found, however, that higher levels
of fatigue among those with an AD history is, at least in part, a
function of enduring levels of distress.
The temporal design of the study provided a unique opportunity to explore the experience of RA and major AD over time.
For instance, our data show that the first episodes of GAD and
MD appeared at ages that are similar to those found in community studies (31). Likewise, we found rates of both lifetime and
current GAD and MD in our sample that are approximately the
same as those found in community samples, where 5% to 9% of
women report current MD, 3% report current GAD, 10% to 25%
of women report lifetime MD, and 5% report lifetime GAD
(31). Thus, these two major ADs appear as “on-time” and expected events rather than as events that occur in a cause or effect
relation with the onset of RA. In addition, we were able to show
how fatigue changes over time. We found that within individuals, levels of fatigue increase slowly over time and in a linear
fashion. People with a history of AD have higher initial fatigue
(10% higher), but their fatigue does not worsen at a faster rate
over time. In fact, changes in fatigue tended to be smaller year to
year for this group. They start with higher levels of fatigue and
continue to report higher levels of fatigue over time. Finally, we
found that within individuals, changes in distress from year to
year are associated with changes in fatigue. However, people
with higher levels of distress averaged over the study period had
smaller distress–fatigue slopes. This suggests that for individuals with higher overall distress, fatigue is higher overall but is
less reactive to changes in distress year to year.
These findings extend our earlier work demonstrating that
fatigue, a common and debilitating symptom of RA, is linked to
a history of AD. The link is not trivial, as our findings suggest
that nearly 20% of RA patients are at risk for levels of fatigue
that are a full 10% higher than those without a history, and the
higher levels persist over 7 years. The relevance of affective history for patients with RA joins a small but growing literature
showing the lifetime vulnerability for disability (9), chronic pelvic pain (14), the persistence of fatigue in chronic fatigue syndrome (10), the risk of coronary artery disease (12), and readmission for unstable angina (13), among people with both an
AD history and other medical conditions.
These findings are important because they point out the
far-reaching effects of affective history on the quality of life of
individuals over time. To the extent that fatigue in RA contrib-
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utes to increased utilization of rheumatology services (4), as
well as work disability (44), early treatment could result in savings to individuals and society. These findings also suggest that
sustained distress, even in the absence of major AD, may also
warrant intervention.
Our findings also demonstrate the importance of examining both within-person and between-person associations before drawing conclusions regarding the relation between fatigue and distress. Within individuals, changes in distress and
changes in fatigue were positively related. However, fatigue
was less reactive to distress among patients experiencing more
distress (more likely to be those with a history). Thus, patients
with high levels of distress and high levels of fatigue do not
necessarily experience distress-contingent fatigue (or fatigue-contingent distress).
Future studies should explore other mechanisms such as
stable personality characteristics (19) and altered biochemical
processes (16,17) that would help explain higher levels of either
perceived or actual fatigue. Our understanding of the experience
of fatigue among those with past AD and current high distress
would also be enhanced with the use of a multidimensional measure of fatigue. Although we had only a single indicator of fatigue in this study, in a follow-up study from the same panel, we
found group differences in fatigue of the same magnitude and in
the same direction for both our single item indicator and Belsia’s
Multidimensional Assessment of Fatigue Scale (3). In addition,
we found a high correlation (r = .69) between the two measures.
Thus, the group effect is robust across both the single item and
the multidimensional indicator of fatigue. However, further insights into the nature of the differences in fatigue reported between those with and without a history of AD awaits future studies using a multidimensional measure.
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